Nephros (NEPH) to Release Earnings on Thursday

Nephros (NASDAQ:NEPH) is projected to issue its Q4 2025 results after the market closes on Thursday, March 12th. Analysts expect Nephros to post earnings of $0.01 per share and revenue of $4.4510 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:30 PM ET.

Nephros Trading Down 0.5%

Shares of NASDAQ NEPH opened at $3.87 on Friday. Nephros has a 12-month low of $1.49 and a 12-month high of $6.42. The stock’s fifty day simple moving average is $4.33 and its two-hundred day simple moving average is $4.65. The stock has a market capitalization of $41.14 million, a PE ratio of 29.77 and a beta of 1.42.

Institutional Investors Weigh In On Nephros

Institutional investors have recently bought and sold shares of the company. Topline Capital Management LLC grew its holdings in Nephros by 13.1% in the second quarter. Topline Capital Management LLC now owns 477,449 shares of the company’s stock worth $1,953,000 after purchasing an additional 55,360 shares during the last quarter. Quadrature Capital Ltd purchased a new stake in shares of Nephros during the 4th quarter valued at $112,000. Marshall Wace LLP purchased a new stake in shares of Nephros during the 4th quarter valued at $107,000. Renaissance Technologies LLC boosted its position in shares of Nephros by 25.8% in the 4th quarter. Renaissance Technologies LLC now owns 103,772 shares of the company’s stock worth $506,000 after purchasing an additional 21,272 shares in the last quarter. Finally, Essex Investment Management Co. LLC boosted its position in shares of Nephros by 57.1% in the 4th quarter. Essex Investment Management Co. LLC now owns 38,984 shares of the company’s stock worth $190,000 after purchasing an additional 14,162 shares in the last quarter. 41.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “hold (c)” rating on shares of Nephros in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.00.

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.